In the wake of the greatest public health crisis in recent memory, the role of the pharma and biopharma industry in the lives of populations globally has taken on a growing importance as it fights to take on the Covid-19 pandemic.
Cytiva’s Global Biopharma Resilience Index - based on a survey of more than 1,000 senior biopharma executives - takes a holistic look at the industry across five key pillars at a time when its health is vital. Fresh data shows there is work to be done to secure its future.
To dive into the highlights and key findings of the index, see the pillars headlining each article, and take a closer look at the interactive data visualisation below.
A gap between high income and lower income countries needs to be bridged to avert shortages of critical drug supplies, and disruptions to global supply chains expose lacking support for talent and manufacturing in domestic markets.
But through insights from leading experts, the industry can blaze a trail forward to a more resilient future. Here’s the state of pharma and biopharma in the midst of its biggest challenge yet.
Biopharma 2021: The resilience rethink
In an age of crisis, can the biopharma industry withstand global shocks?
Global or local? Biopharma's supply chain challenge
Drug shortages are common and is a reality that cannot be wished away.
Biopharma reaches for homegrown talent
Talent is particularly vital for pharma and biopharma, making a shallow pool of local talent a real issue.
Biopharma R&D needs more collaboration
Of all the lessons for Big Pharma from the Covid-19 pandemic, there is one that is likely to endure: collaboration.
Shifting biopharma's manufacturing into the fast lane
As the past year has shown, the ability to be both malleable and swift are powerful assets in the face of virulent diseases.